Skip to main content

Talazoparib News

Pfizer’s Talzenna (talazoparib) in Combination with Xtandi (enzalutamide) Receives U.S. FDA Approval for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

NEW YORK--(BUSINESS WIRE) June 20, 2023 – Pfizer (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Talzenna (talazoparib), an oral poly ADP-ribose polymerase...

FDA Approves Talzenna (talazoparib) for gBRCAm HER2-Negative Locally Advanced or Metastatic Breast Cancer

On October 16, 2018, the Food and Drug Administration approved talazoparib (Talzenna, Pfizer Inc.), a poly (ADP-ribose) polymerase (PARP) inhibitor, for patients with deleterious or suspected...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Breast Cancer, Prostate Cancer

Talazoparib patient information at Drugs.com